RecoverLINK Technology Pilot for HF Patients

Heart Failure Clinical Trial

Official title:

Pilot to Assess Feasibility of Using RecoverLINK Technology to Supplement Outpatient Care for Heart Failure Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02815085
• Other study ID #: IF1793800
• Status: Completed
• Phase: N/A
• Start date: February 2016
• Est. completion date: June 2018

Study information

• Verified date: August 2018
• Source: RecoverLINK
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective is to examine feasibility of incorporating RecoverLINK into the standard of care as a function of (i) user engagement, (ii) user satisfaction, and (iii) workflow efficiency. As secondary objectives, the investigators will collect preliminary data to examine the association between patient engagement with the RecoverLINK app and (i) changes in patient knowledge and behavior, and (ii) hospital readmission(s) at 30, 60, and 90-day time periods post-enrollment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: June 2018
• Est. primary completion date: April 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Heart failure (HF) patients with a rapid follow up appointment scheduled at the Mount Sinai HF clinic

• English-speaking

• With either access to (i) an iOS smart device or (ii) wifi at-home

Exclusion Criteria:

Patients meeting any of the following criteria:

• A heart transplant

• A mechanical circulatory support (MCS) device

• An altered mental status

• Serious co-morbidities (as identified by Mount Sinai team)

• Cognitive impairments (as identified by Mount Sinai team)

• Inability to use technology (as identified by Mount Sinai team)

Related Conditions & MeSH terms

• Heart Failure

Intervention

Other:
• RecoverLINK technology
HF patients will receive the RecoverLINK app upon study enrollment for 30-days. The Mount Sinai HF care team will interact with patients via the RecoverLINK cloud-based system during this period

Locations

Country	Name	City	State
United States	The Mount Sinai Hospital	New York	New York

Sponsors (3)

Lead Sponsor	Collaborator
RecoverLINK	Digital Health Marketplace (previously Pilot Health Tech NYC), Mount Sinai Hospital, New York

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	User engagement: # symptom surveys completed/30 days		30 days
Primary	User satisfaction: Percent patients report "satisfied" via post-program survey		30 days
Primary	Workflow efficiency: mean/median time to resolution of patient alerts		30 days
Secondary	Mean difference in pre/post SCHIFI score		30 days
Secondary	Hospital admission		30, 60, 90 days